Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a biotechnology leader with a market capitalization of $151.3 billion and impressive gross margins of nearly 69%, reported that its Phase 3 DeLLphi-304 ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a biotechnology leader with a market capitalization of $151.3 billion and impressive gross margins of nearly 69%, reported that its Phase 3 DeLLphi-304 ...

SCHD, thanks to its exposure to mature, dividend-paying companies, is withstanding the market shock better. Click here for ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Among the largest underlying components of QQQM, in trading today Comcast Corp (Symbol: CMCSA) is off about 0.6%, Amgen Inc (Symbol: AMGN) is off about 0.9%, and PayPal Holdings Inc (Symbol ...

Amgen obtained FDA approval for the label expansion of its rare disease drug, Uplizna (inebilizumab), for a new indication. The regulatory body has now approved Uplizna for the treatment of adults ...